ReNeuron Group plc Posting of AR and Accounts and Notice of AGM (7906I)
16 Agosto 2021 - 08:20AM
UK Regulatory
TIDMRENE
RNS Number : 7906I
ReNeuron Group plc
16 August 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Posting of Annual Report and Accounts and Notice of AGM
ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell
therapy development company, announces that its Annual Report and
Accounts for the year ended 31 March 2021 and the Notice of the
2021 Annual General Meeting ("AGM") have today been sent to
shareholders and are also available on the Company's website at
www.reneuron.com .
ReNeuron's AGM will be held at 10.00am on Thursday 16 September
2021 in the Hilton London Paddington, 146 Praed Street, London, W2
1EE.
At the time of publication of the notice of AGM, the Government
has lifted most legal restrictions relating to public gatherings
that had previously been in place due to the ongoing COVID-19
Pandemic. In line with this, the Board welcomes the opportunity to
invite shareholders to attend the AGM in person. Should this
situation change, shareholders will be notified though our website
www.reneuron.com and, where appropriate by RNS.
Shareholders are encouraged to send any questions for the
Chairman to info@reneuron.com at least 48 hours prior to the
meeting. Where appropriate, such questions and answers will be
collated and later published, together with full voting details, in
the Investor Centre of the Company's website at www.reneuron.com
.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOADKABDNBKDNFD
(END) Dow Jones Newswires
August 16, 2021 09:20 ET (13:20 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024